Marin Lozić, Vasilije Stambolija, Ivan Krezić, Aleksandra Dugandžić, Gordana Živanović-Posilović, Slaven Gojković, Josip Kovačević, Luka Vrdoljak, Ivan Mirković, Antonio Kokot, Andreja Petrović, Katarina Horvat Pavlov, Domagoj Drmić, Jelena Šuran, Alenka Boban Blagaić, Sven Seiwerth, Predrag Sikirić,
Recently, the pentadecapeptide BPC 157-induced counteraction of bupivacaine cardiotoxicity has been reported. Medication includes (i) lidocaine-induced local anesthesia via intraplantar application and axillary and spinal (L4-L5) intrathecal block, (ii) lidocaine-induced arrhythmias, (iii) convulsions, and (iv) lidocaine-induced HEK293 cell depolarisation. BPC 157 applications (intraplantar, intraperitoneal, and intragastric) were given (i) immediately after lidocaine, (ii) 10 min after, or (iii) 5 min before. ...
Tópico(s): Nausea and vomiting management
2020 - Hindawi Publishing Corporation | Emergency Medicine International
Marin Lozić, Vasilije Stambolija, Josip Kovačević, Gordana Živanović-Posilović, Jelena Šuran, Božidar Duplančić, Ivan Mirković, Antonio Kokot, Domagoj Drmić, Sven Seiwerth, Predrag Sikirić,
We documented that the stable gastric pentadecapeptide BPC 157 antagonized local anaesthetic effect of lidocaine. BPC 157 (LD1 not achieved) was implemented as an anti‐ulcer peptide in inflammatory bowel disease trials and now in a multiple sclerosis trial (Curr Pharm Des. 2018;24(18):1990–2001). Stable gastric pentadecapeptide BPC 157 was previously shown as a cardioprotective compound in a model of arrhythmia induced by bupivacaine toxicity where it counteracts arrhythmias and prevents lethal outcome ( ...
Tópico(s): Potassium and Related Disorders
2019 - Wiley | The FASEB Journal